What Xediton Pharmaceuticals does

Xediton Pharmaceuticals Inc. is a privately held Canadian specialty pharmaceutical company headquartered in Oakville, Ontario, founded in 2007. The company operates an asset-light business model focused on licensing, commercializing, and managing the lifecycle of branded pharmaceutical products in the Canadian market, without engaging in proprietary drug discovery or development. Its portfolio spans 31 prescription medications across multiple therapeutic areas — including Oncology, Anti-Infectives, Cardiovascular, Gastroenterology, Pain, CNS, Ophthalmology, Renal, and Weight Management — sourced through long-term partnerships with global pharmaceutical companies such as Cheplapharm Arzneimittel, Sebela Pharmaceuticals, Grunenthal Group, Melinta Therapeutics, and Quantum Genomics. The company has stated a focus on specialty care, matured/established brands, niche products, and both patented and non-patented products.

The company generates revenue primarily through product sales of prescription medications, medical devices, and over-the-counter (OTC) products in Canada, distributed through all major Canadian pharmaceutical wholesalers, hospital buying groups, and a territory-based direct sales force. Xediton's go-to-market combines a sales-led motion for healthcare professional engagement with a channel-partner strategy for international licensors seeking Canadian market entry. Value-added services include Health Canada regulatory submissions, market access and reimbursement management, sales and marketing execution, and full lifecycle management of licensed products. Pricing is not publicly disclosed, with customers directed to phone/email customer service for quotes.

In February 2025, Xediton completed the acquisition of Valeo Pharma Inc. through a court-approved share purchase agreement under the Companies' Creditors Arrangement Act (CCAA), adding wholly-owned subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc. and expanding the portfolio into Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products. The company remains privately held with no public funding rounds, venture capital investment, or revenue disclosures documented in the available materials; George Gafrey serves as President and CEO.

Name

Xediton Pharmaceuticals

Legal name

Xediton Pharmaceuticals Inc.

Website

https://xediton.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company that licenses, commercializes, and manages branded prescription drugs, medical devices, and OTC products across multiple therapeutic areas for the Canadian market through partnerships with global pharmaceutical firms.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Specialty pharmaceuticals
• Prescription medications
• Drug commercialization
• Pharmaceutical licensing
• Medical devices

Headquarters

HQ city

Oakville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Xediton generates revenue through the sale of prescription medications, medical devices, and over-the-counter (OTC) products in the Canadian market. Products include specialty care medications, matured/established brands, niche products, and both patented and non-patented products.
2. Licensing and Commercialization Rights: Xediton obtains exclusive rights to commercialize products in Canada through licensing agreements with international pharmaceutical partners. The company is responsible for registration and commercialization of licensed products in the Canadian market, including regulatory submissions to Health Canada.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Xediton licenses, acquires, and commercializes specialty pharmaceutical products—including prescription medications, medical devices, and OTC products—for the Canadian market. The company handles regulatory submissions to Health Canada, market access, and sales through wholesalers, hospitals, and a territory-based sales force, partnering with global pharmaceutical companies to bring established and innovative drugs to Canadian patients.

Product overview

Xediton Pharmaceuticals is a privately held Canadian specialty pharmaceutical company founded in 2007, headquartered in Oakville, Ontario. The company operates through licensing and acquisition of pharmaceutical products for the Canadian market. The portfolio consists of 31 prescription medications spanning multiple therapeutic areas including Oncology (Anandron, Vepesid, Vesanoid), Anti-Infectives (Cytovene, Fungizone, Valcyte), Cardiovascular (Inhibace, Inhibace Plus, Visken, Viskazide), Gastroenterology (Losec, Vimovo), Neurology/Psychiatry (Rivotril), Immunology/Rheumatology (Ridaura), Urology/Endocrinology (Suprefact), Ophthalmology (Visudyne), and Weight Management (Xenical). The company also commercializes products under licensing agreements with partners such as Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE). Following the February 2025 acquisition of Valeo Pharma Inc., the company expanded its portfolio to include products in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products.

Differentiator

Problem solved

Functional benefit

Products and services

• Anandron 50mg Tablets Nilutamide nonsteroidal antiandrogen medication used for metastatic prostatic carcinoma; dispensed via Canadian wholesalers and hospitals.
• Cytovene 500mg Injection Ganciclovir antiviral agent for treatment of cytomegalovirus (CMV) retinitis; sold to Canadian hospitals and wholesalers.
• Fungizone 50mg Vial Amphotericin B antifungal agent for disseminated mycotic infections; distributed through Canadian wholesalers.
• Inhibace 5mg Tablets Cilazapril angiotensin-converting enzyme inhibitor used for hypertension and congestive heart failure.
• Inhibace Plus 5/12.5mg Tablets Combination of cilazapril and hydrochlorothiazide (ACE inhibitor/diuretic) used for hypertension.
• Losec 20mg Capsules Omeprazole proton pump inhibitor (PPI) for peptic ulcer disease and acid reflux.
• Losec 20mg MUPS Tablets Omeprazole proton pump inhibitor (PPI) in MUPS formulation for peptic ulcer disease and acid reflux.
• One Alpha 0.25mcg Capsules Alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
• One Alpha 1mcg Capsules Alfacalcidol vitamin D analogue (1mcg strength) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
• One Alpha 2mcg IV 10X0.5ml Ampoules Intravenous alfacalcidol vitamin D analogue for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
• One Alpha 2mcg IV 10X1ml Ampoules Intravenous alfacalcidol vitamin D analogue (higher volume ampoule) for management of hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
• One Alpha 2mcg/mL 20ml Drops Oral drops formulation of alfacalcidol vitamin D analogue for hypocalcemia, secondary hyperparathyroidism and osteodystrophy.
• Ridaura 3mg Capsules Auranofin antirheumatic agent for active rheumatoid arthritis.
• Rivotril 0.5mg Tablets Clonazepam anticonvulsant for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).
• Rivotril 2mg Tablets Clonazepam anticonvulsant (higher strength) for myoclonic and akinetic seizures and petit mal variant (Lennox-Gastaut Syndrome).
• Rythmodan 100mg Capsules Disopyramide antiarrhythmic agent for documented life-threatening ventricular arrhythmias.
• Suprefact 6.3mg Depot Buserelin (Buserelin Acetate) LHRH analogue for hormone-dependent advanced carcinoma of the prostate gland (Stage D).
• Suprefact 9.45mg Depot Buserelin (Buserelin Acetate) LHRH analogue (higher dose) for hormone-dependent advanced carcinoma of the prostate gland (Stage D).
• Suprefact Injection 1mg/ml Buserelin (Buserelin Acetate) LHRH analogue injectable solution for hormone-dependent advanced prostate carcinoma.
• Valcyte 450mg Tablets Valganciclovir antiviral agent for cytomegalovirus (CMV) retinitis.
• Valcyte 50mg/ml Valganciclovir oral solution antiviral agent for cytomegalovirus (CMV) retinitis.
• Vepesid 50mg Capsules Etoposide antineoplastic agent for small and non-small cell carcinoma of the lung, malignant lymphoma, and testicular malignancies.
• Vesanoid 10mg Capsules Tretinoin differentiation inducing agent for acute promyelocytic leukemia.
• Vimovo 375/20mg Tablets Combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
• Vimovo 500/20mg Tablets Higher strength combination of naproxen and esomeprazole NSAID with proton pump inhibitor for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
• Viskazide 10/50 Tablets Pindolol/hydrochlorothiazide antihypertensive combination agent for hypertension.
• Viskazide 1025 Tablets Pindolol/hydrochlorothiazide antihypertensive combination agent (different ratio) for hypertension.
• Visken 10mg Tablets Pindolol antihypertensive and antianginal agent for hypertension and angina pectoris.
• Visken 5mg Tablets Pindolol antihypertensive and antianginal agent (lower strength) for hypertension and angina pectoris.
• Visudyne 15mg Injection Verteporfin photosensitizing agent for classic subfoveal choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis.
• Xenical 120mg Capsules Orlistat anti-obesity agent and gastrointestinal lipase inhibitor for obesity management, weight loss and weight maintenance.
• Melinta Therapeutics Anti-Infective Portfolio (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) In-licensed portfolio of four novel anti-infective prescription products from Melinta Therapeutics (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) registered and commercialized by Xediton in Canada for pathogens on Canada's Pathogens of Interest List.
• Valeo Pharma-Acquired Specialty Pharmaceutical Portfolio Specialty pharmaceutical portfolio in Respiratory/Allergy, Ophthalmology, and Hospital Specialty Products, retained through the February 2025 acquisition of Valeo Pharma Inc. (including subsidiaries Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Valeo Pharma Inc.coreStrategic or Co-development Partner · 4 February 2025Xediton completed a share purchase agreement to acquire 100% of Valeo Pharma Inc., which was under proceedings under the Companies' Creditors Arrangement Act (CCAA). The transaction was approved by the Quebec Superior Court on February 4, 2025. Xediton retained Valeo's existing licenses, operating permits, supply agreements, product listing agreements, intellectual property, and ownership of Valeo's subsidiaries (Valeo Pharma Corp. and VPI Pharmaceuticals Inc.).
• Melinta TherapeuticscoreStrategic or Co-development Partner · 15 May 2023Exclusive commercialization and licensing agreement for four novel anti-infective products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and VABOMERE (meropenem and vaborbactam). Xediton is responsible for registration and commercialization of these products in Canada. These products have been approved by the US FDA and may be eligible for Priority Review by Health Canada.
• Cheplapharm Arzneimittel GmbHcoreStrategic or Co-development PartnerLong-term international partnership for bringing pharmaceutical products to the Canadian market. Cheplapharm is a German pharmaceutical company with a focus on established medicines.
• Sebela PharmaceuticalscoreStrategic or Co-development PartnerStrategic partnership with Sebela Pharmaceuticals for product licensing and commercialization in Canada. Sebela is a global pharmaceutical company.
• Grunenthal GroupcoreStrategic or Co-development PartnerInternational partnership with Grunenthal Group, a German pharmaceutical company specializing in pain management and other therapeutic areas, to bring products to the Canadian market.
• Quantum GenomicsminorStrategic or Co-development PartnerPartnership with Quantum Genomics, a biopharmaceutical company focused on cardiovascular and neurological diseases, for potential product introduction to Canadian market.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Duchesnay: Canadian specialty pharma focused on women's health, oncology, and rare diseases; comparable in-licensing and commercialization profile within the Canadian market.
• Cipher Pharmaceuticals: Canadian specialty pharma that licenses, acquires, and commercializes niche and mature products across multiple therapeutic categories in Canada, sharing Xediton's lean commercialization approach and geographic concentration.
• Knight Therapeutics: Montreal-based Canadian specialty pharmaceutical company with an in-licensing and commercialization model very similar to Xediton's, focused on acquiring and commercializing innovative and established products in Canada and select emerging markets.
• HLS Therapeutics: Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage products, including established brands, in Canada — a direct analogue in both therapeutic strategy and Canadian-only footprint.
• Searchlight Pharma: Canadian specialty pharma that in-licenses and commercializes branded prescription, OTC, and diagnostic products in Canada — a closely analogous in-licensing commercialization peer to Xediton.
• Paladin Labs: Canadian specialty pharma (acquired by Endo) historically built on in-licensing niche and established products for the Canadian market — directly comparable business model to Xediton's pre-Valeo operations.

Others

• Melinta Therapeutics: U.S. anti-infectives company that licensed four products (BAXDELA, KIMYRSA, ORBACTIV, VABOMERE) to Xediton for Canada; a direct partner and therefore a closely adjacent rather than competing entity.
• Cheplapharm Arzneimittel GmbH: German specialty pharma specializing in established-brand lifecycles and a long-term Xediton partner; a useful upstream comparator for the mature-brand commercialization model Xediton runs in Canada.

Broad incumbents

• Apotex: Canada's largest generic pharmaceutical manufacturer and distributor; competes with Xediton for the same Canadian wholesale channel and overlapping prescriber base, though Apotex is a manufacturer rather than a pure commercialization partner.
• Bausch Health Companies: Large Canadian-headquartered specialty pharma with a broad therapeutic-area portfolio and established Canadian commercial infrastructure; overlaps with Xediton on the specialty/mature-brand strategy but at vastly greater scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/XeditonPharma
• YouTubeyoutube.com/channel/UC5HYyxV7aWU8ObfMzqMwYUw
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/xeditonpharmaceuticals
• Pinterestpinterest.com/xeditonpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xediton Pharmaceuticals